These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27221141)

  • 1. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
    Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
    Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
    BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess G; Borker R; Fonseca E
    Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
    Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
    Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
    Uccello M; Alam T; Abbas H; Nair A; Paskins J; Faust G
    Clin Genitourin Cancer; 2019 Jun; 17(3):e658-e663. PubMed ID: 31000484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
    Queiroz Muniz D; Ratto B; Yang H; Zhao J; Jenkins M; Signorovitch J; Dezzani L; Salman P; Lema Medina M; Lopera D; Lerzo G; Del Castillo C; Chacon M; Martin A; Campos-Gomez S
    Adv Ther; 2019 Dec; 36(12):3446-3457. PubMed ID: 31630333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
    Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
    Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
    Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
    J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.
    De Groot S; Sleijfer S; Redekop WK; Oosterwijk E; Haanen JB; Kiemeney LA; Uyl-de Groot CA
    BMC Cancer; 2016 Jun; 16():364. PubMed ID: 27286871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.